Anika Therapeutics, Inc. (ANIK)
| Market Cap | 331.76M |
| Revenue (ttm) | 163.31M |
| Net Income (ttm) | -24.58M |
| Shares Out | 14.64M |
| EPS (ttm) | -1.69 |
| PE Ratio | n/a |
| Forward PE | 78.74 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 44,637 |
| Open | 22.28 |
| Previous Close | 22.64 |
| Day's Range | 22.28 - 23.01 |
| 52-Week Range | 16.54 - 32.33 |
| Beta | 0.73 |
| Analysts | Buy |
| Price Target | 25.50 (+12.53%) |
| Earnings Date | Nov 2, 2023 |
About ANIK
Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and bone preserving joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief fr... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for ANIK stock is "Buy." The 12-month stock price forecast is $25.5, which is an increase of 12.53% from the latest price.
News
Anika Announces First Surgeries Performed using the Integrity™ Implant System, a Regenerative Hyaluronic Acid-Based Patch System for Rotator Cuff Repairs, Commencing Limited Market Release
Integrity marks Anika's entrance into the fast-growing $150 million+2 U.S. rotator cuff augmentation market and expansion of its proprietary hyaluronic acid (HA) regenerative portfolio
Anika to Participate in Upcoming Investor Conferences
BEDFORD, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that Dr. Cheryl Blanch...
Anika Reports Third Quarter 2023 Financial Results and Raises Full-Year 2023 Financial Guidance on Growing Momentum Across the Business
Revenue Growth Exceeded Expectations in the Third Quarter and Year-To-Date, with Joint Preservation and Restoration up 14% and 10% and OA Pain Management up 2% and 11%, Respectively
Anika to Issue Third Quarter 2023 Financial Results on Thursday, November 2, 2023
BEDFORD, Mass., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans...
Anika Announces the Full Market Release of the RevoMotion™ Reverse Shoulder Arthroplasty System during the 2023 Orthopaedic Summit: Evolving Technologies (OSET) Annual Meeting
RevoMotion Reverse Shoulder Arthroplasty System significantly expands Anika's shoulder arthroplasty portfolio and provides a bone conserving and innovative solution in the $1 billion1 U.S. reverse sho...
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BEDFORD, Mass., Sept. 15, 2023 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that on September 5, ...
Anika to Participate in the Sidoti Small Cap Virtual Investor Conference
BEDFORD, Mass., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that management will ...
Anika Receives 510(k) Clearance for Integrity™ Implant System, a Regenerative Hyaluronic Acid-Based Patch System for Augmentation of Rotator Cuff Repairs
Complete Integrity Implant System is now fully cleared; targeting launch in Q1-2024 Integrity is highly differentiated by its knitted structure, resulting in higher strength and greater regenerative c...
Anika Reports Second Quarter 2023 Financial Results
Double Digit Q2 Revenue Growth Driven by Strong OA Pain Management Growth of 22%; Raising Low-End of Full-Year Guidance Range on Positive Year-to-Date Performance
Anika to Issue Second Quarter 2023 Financial Results on Tuesday, August 8, 2023
BEDFORD, Mass., July 20, 2023 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans...
Anika Showcases Highly Differentiated Joint Preservation and Restoration Portfolio at the 2023 AOSSM Annual Meeting
Anika's new X-Twist™ Fixation System, combined with its ACE Award-Winning Tactoset® for hardware augmentation and autologous bone morrow aspirate, provide time-saving regenerative solutions for Sports...
Anika Completes Enrollment in Hyalofast® U.S. Pivotal Phase III Study Achieving Key Milestone
Hyalofast – a single-stage, off-the-shelf, resorbable, hyaluronic acid scaffold for cartilage repair – is marketed in over 35 countries outside the U.S. where it has been clinically demonstrated to ...
Anika Reports First Quarter 2023 Financial Results
Positive Start to 2023 Revenue Growth with OA Pain Management Up 8% and Joint Preservation and Restoration Up 11% Positive Start to 2023 Revenue Growth with OA Pain Management Up 8% and Joint Preserva...
Anika to Issue First Quarter 2023 Financial Results on Tuesday, May 9, 2023
BEDFORD, Mass., April 19, 2023 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plan...
Anika Enters Into Cooperation Agreement with Caligan Partners
Gary Fischetti Joins Anika Board Announces Share Repurchase Program Forms Capital Allocation Committee BEDFORD, Mass., April 13, 2023 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK) (“Anik...
Anika to Participate in the 22nd Annual Needham Virtual Healthcare Conference
BEDFORD, Mass., April 12, 2023 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that management will ...
Anika Continues to Expand Addressable Market for Tactoset® Injectable Bone Substitute with Additional 510(k) Clearance from FDA
Tactoset cleared by the FDA to be combined with autologous bone marrow aspirate, a core element for regenerative healing
Anika Files Preliminary Proxy Statement
BEDFORD, Mass., March 27, 2023 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK) (“Anika” or the “Company”), a global joint preservation company in early intervention orthopedics, today anno...
Anika Highlights Products in High Growth Segments of Joint Preservation during the 2023 AAOS Annual Meeting
Recently Commenced Full Market Release of X-Twist™ Fixation System, a Cornerstone Product in Anika's Sports Medicine Portfolio
Anika Reports Fourth Quarter and Year-End Fiscal 2022 Financial Results
Delivered Fourth Quarter Revenue Growth of 11% and Full Year 2022 Revenue Growth of 6%
Anika to Participate in the Canaccord Genuity Musculoskeletal Conference
BEDFORD, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that management will p...
Anika to Issue Fourth Quarter and Year-End 2022 Financial Results on Monday, March 6, 2023
BEDFORD, Mass., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans...
Anika Issues Statement
BEDFORD, Mass., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today issued the following statement i...
Caligan Partners Issues Open Letter to Anika Board
Believes Current Board's Strategic Missteps and Poor Capital Allocation Has Led to Significant Underperformance Offers Three Actions for Significant Change, Including Strategic Review NEW YORK , Feb. ...
Anika Announces First Surgeries Performed Using the New RevoMotion™ Reverse Shoulder Arthroplasty System and Commences Limited Market Release in the United States
RevoMotion significantly expands Anika's shoulder arthroplasty portfolio and provides a new solution in the over $800 million U.S. reverse shoulder market